News | October 29, 2021
Laurus Labs PAT at Rs 201.90 cr. in Q2FY21
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
The NFI is published to promote the rational use of medicines in the country.
It launched the most advanced "DTAS" (Direct to Angio Suite) & State of the art ‘Neuro-Angio’ technology
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated
